Illumina (NASDAQ:ILMN) Stock Rating Cut to Hold at Wall Street Zen

Key Points

• Wall Street Zen downgraded Illumina from “Buy” to “Hold.” Overall analyst sentiment is also “Hold,” with 10 Buy, six Hold and two Sell ratings and a consensus price target of $214.69.
• Illumina reported quarterly EPS of $1.31, beating estimates of $1.23, while revenue rose 9.4% year over year to $1.16 billion. The company guided to fiscal 2026 EPS of $5.30–$5.40.
• Insiders sold heavily during the last quarter, including director Keith Meister’s sale of 119,501 shares; total insider sales reached 2.06 million shares valued at approximately $436.5 million.

Illumina (NASDAQ:ILMN - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday, Wall Street Zen reports.

Other analysts have also recently issued research reports about the company. Weiss Ratings restated a "hold (c)" rating on shares of Illumina in a research report on Monday, August 31st. Citigroup increased their target price on shares of Illumina from $95.00 to $113.00 and gave the stock a "sell" rating in a report on Monday, August 3rd. Guggenheim upped their price target on shares of Illumina from $226.00 to $305.00 and gave the stock a "buy" rating in a research report on Thursday. JPMorgan Chase & Co. increased their price objective on shares of Illumina from $220.00 to $230.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Finally, TD Cowen increased their price target on Illumina from $192.00 to $210.00 and gave the stock a "hold" rating in a research note on Friday, July 31st. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, Illumina has an average rating of "Hold" and a consensus price target of $214.69.

Illumina Price Performance

NASDAQ ILMN opened at $273.04 on Friday. Illumina has a 52 week low of $88.00 and a 52 week high of $280.17. The firm has a market capitalization of $41.23 billion, a P/E ratio of 50.94, a PEG ratio of 3.77 and a beta of 1.41. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The company has a 50-day moving average price of $219.37 and a 200-day moving average price of $175.55.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the firm posted $1.19 earnings per share. The firm's revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Illumina will post 5.36 earnings per share for the current year.

Insider Buying and Selling at Illumina

In other news, Director Keith Meister sold 119,501 shares of Illumina stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the sale, the director directly owned 770,350 shares of the company's stock, valued at approximately $168,244,440. The trade was a 13.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Christensen Wedel sold 1,033 shares of the business's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 2,061,850 shares of company stock worth $436,479,102. Corporate insiders own 2.90% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. QRG Capital Management Inc. lifted its holdings in Illumina by 8.1% during the second quarter. QRG Capital Management Inc. now owns 7,261 shares of the life sciences company's stock worth $1,277,000 after buying an additional 546 shares during the period. Envestnet Portfolio Solutions Inc. boosted its position in Illumina by 18.6% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 6,935 shares of the life sciences company's stock valued at $1,219,000 after acquiring an additional 1,090 shares in the last quarter. Tidal Investments LLC increased its holdings in shares of Illumina by 10.3% in the 2nd quarter. Tidal Investments LLC now owns 93,728 shares of the life sciences company's stock valued at $16,480,000 after acquiring an additional 8,726 shares during the period. MCF Advisors LLC increased its holdings in shares of Illumina by 172.4% in the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company's stock valued at $28,000 after acquiring an additional 100 shares during the period. Finally, National Pension Service raised its position in shares of Illumina by 246.7% in the 2nd quarter. National Pension Service now owns 369,856 shares of the life sciences company's stock worth $65,032,000 after acquiring an additional 263,172 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.